name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
A1020V	g.C3059T	p.A1020V			24621	S	S	MISSENSE	745	749	795						741	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A1298V	g.C3893T	p.A1298V			4158	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		742	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A134V	g.C401T	p.A134V			28674	N	N	MISSENSE	749	749	795						744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A1997V	g.C5990T	p.A1997V			6255	ORF1ab	ORF1a	MISSENSE	748	749	795	mask	highly_homoplasic,narrow_src	nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		718	T=30	30	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A2123V	g.C6368T	p.A2123V			6633	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		736	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A222V	g.C665T	p.A222V			22227	S	S	MISSENSE	749	749	795						738	T=11	11	T	C	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies."	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A222V	g.C665T	p.A222V			22227	S	S	MISSENSE	749	749	795						738	T=11	11	T	C	humoral response durability	Brehm et al. (2021)	https://dx.doi.org/10.3390%2Fv13040661	'D614G'	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A222V	g.C665T	p.A222V			22227	S	S	MISSENSE	749	749	795						738	T=11	11	T	C	reinfection	Brehm et al. (2021)	https://dx.doi.org/10.3390%2Fv13040661	'D614G'	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A243S	g.G727T	p.A243S			22289	S	S	MISSENSE	749	749	795						744	T=5	5	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A2470A	g.G7410T	p.A2470A			7675	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		697	T=52	52	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A2994T	g.G8980A	p.A2994T			9245	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		738	A=11	11	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A3379V	g.C10136T	p.A3379V			10401	ORF1ab	ORF1a	MISSENSE	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		720	T=29	29	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A3730A	g.C11190T	p.A3730A			11455	ORF1ab	ORF1a	SILENT	46	46	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A3945A	g.C11835T	p.A3945A			12100	ORF1ab	ORF1a	SILENT	749	749	795			nsp8	produced by both pp1a and pp1ab		4	T=745	745	T	C						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
A43T	g.G127A	p.A43T			27882	ORF7b	ORF7b	MISSENSE	46	46	795						33	A=13	13	A	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A4408V	g.C13223T	p.A4408V			13487	ORF1ab	ORF1b	MISSENSE	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A4841V	g.C14522T	p.A4841V			14786	ORF1ab	ORF1b	MISSENSE	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		739	T=10	10	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A5342V	g.C16025T	p.A5342V			16289	ORF1ab	ORF1b	MISSENSE	46	46	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A5458A	g.A16374T	p.A5458A			16638	ORF1ab	ORF1b	SILENT	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		742	T=7	7	T	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A54V	g.C161T	p.A54V			25553	ORF3a	ORF3a	MISSENSE	749	749	795						744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A5561S	g.G16681T	p.A5561S			16945	ORF1ab	ORF1b	MISSENSE	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		727	T=22	22	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A656V	g.C1967T	p.A656V			2232	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		738	T=11	11	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
A65V	g.C194T	p.A65V			28087	ORF8	ORF8	MISSENSE	46	46	795						25	T=21	21	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A6802T	g.G20404A	p.A6802T			20668	ORF1ab	ORF1b	MISSENSE	46	46	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		45	A=1	1	A	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
A7056V	g.C21167T	p.A7056V			21431	ORF1ab	ORF1b	MISSENSE	749	749	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		709	T=40	40	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
C19C	g.C57T	p.C19C			29614	ORF10	ORF10	SILENT	746	749	795						736	T=10	10	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
C4332C	g.C12996T	p.C4332C			13261	ORF1ab	ORF1a	SILENT	749	749	795			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		720	T=29	29	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
C4787C	g.C14361T	p.C4787C			14625	ORF1ab	ORF1b	SILENT	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		723	T=26	26	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
C67C	g.T201C	p.C67C			27594	ORF7a	ORF7a	SILENT	738	749	795						734	C=4	4	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D1184D	g.C3552T	p.D1184D			3817	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		25	T=21	21	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
D138Y	g.G412T	p.D138Y			21974	S	S	MISSENSE	707	749	795						689	T=18	18	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D138Y	g.G412T	p.D138Y			21974	S	S	MISSENSE	707	749	795						689	T=18	18	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D138Y	g.G412T	p.D138Y			21974	S	S	MISSENSE	707	749	795						689	T=18	18	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D138Y	g.G412T	p.D138Y			21974	S	S	MISSENSE	707	749	795						689	T=18	18	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D27D	g.T81C	p.D27D			25473	ORF3a	ORF3a	SILENT	749	749	795						697	C=52	52	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D34V	g.A101T	p.D34V			27994	ORF8	ORF8	MISSENSE	46	46	795						42	T=4	4	T	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
D3Y	g.G7T	p.D3Y			28280	N	N	MISSENSE	749	749	795						255	T=494	494	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D5109N	g.G15325A	p.D5109N			15589	ORF1ab	ORF1b	MISSENSE	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		743	A=6	6	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D5152D	g.C15456T	p.D5152D			15720	ORF1ab	ORF1b	SILENT	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		737	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D5584Y	g.CTCAG16746_16750TTCAT	p.D5584Y			17010	ORF1ab	ORF1b		748	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	TTCAT=25	25	TTCAT	CTCAG						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D5584Y	g.G16750T	p.D5584Y			17010	ORF1ab	ORF1b	MISSENSE	748	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	CTCAT=723	723	CTCAT	CTCAG						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D5584Y	g.G16750T	p.D5584Y			17014	ORF1ab	ORF1b	MISSENSE	46	46	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	T=46	46	T	G						False	B.1.427	B.1.427=True	de_escalated	05-Mar-2021		
D578D	g.T1734C	p.D578D			23296	S	S	SILENT	46	46	795						45	C=1	1	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I', 'W152C', 'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'W152C'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I', 'W152C', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'W152C'	1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	convalescent plasma escape	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	humoral response durability	Brehm et al. (2021)	https://dx.doi.org/10.3390%2Fv13040661	'A222V'	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	reinfection	Brehm et al. (2021)	https://dx.doi.org/10.3390%2Fv13040661	'A222V'	27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	transmissibility	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'L452R'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'S13I', 'W152C', 'L452R'	Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'W152C', 'L452R'	6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'S13I', 'W152C', 'L452R'	Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'S13I', 'W152C', 'L452R'	Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccine neutralization efficacy	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	749	749	795						0	G=749	749	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S13I', 'W152C', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'W152C'	1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	795	795	795						0	G=795	795	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
D828Y	g.G2482T	p.D828Y			2747	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		728	T=21	21	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D98D	g.C294T	p.D98D			28567	N	N	SILENT	749	749	795						742	T=7	7	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
D992D	g.C2976T	p.D992D			3241	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		717	T=32	32	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
E1013D	g.G3039T	p.E1013D			3304	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41	T=5	5	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
E1205A	g.A3614C	p.E1205A			3879	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		251	C=497	497	C	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
E191K	g.G571A	p.E191K			25963	ORF3a	ORF3a	MISSENSE	747	749	795						737	A=10	10	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
E33E	g.A99G	p.E33E			27492	ORF7a	ORF7a	SILENT	741	749	795						737	G=4	4	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
E3X	g.G7T	p.E3X			27762	ORF7b	ORF7b	NONSENSE	739	749	795						731	T=8	8	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
E5188D	g.A15564T	p.E5188D			15828	ORF1ab	ORF1b	MISSENSE	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		45	T=1	1	T	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
E6378D	g.G19134T	p.E6378D			19398	ORF1ab	ORF1b	MISSENSE	42	46	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		37	T=5	5	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
E93D	g.A279C	p.E93D			544	ORF1ab	ORF1a	MISSENSE	749	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		733	C=16	16	C	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F110F	g.C330T	p.F110F			28603	N	N	SILENT	749	749	795						737	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F114Y	g.CTT339_341TTA	p.F114Y			27732	ORF7a	ORF7a		738	749	795						694	TTA=44	44	TTA	CTT						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F2334F	g.C7002T	p.F2334F			7267	ORF1ab	ORF1a	SILENT	746	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		724	T=22	22	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F3100F	g.C9300T	p.F3100F			9565	ORF1ab	ORF1a	SILENT	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
F3132F	g.C9396T	p.F3132F			9661	ORF1ab	ORF1a	SILENT	749	749	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F3568F	g.C10704T	p.F3568F			10969	ORF1ab	ORF1a	SILENT	45	46	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		43	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
F363F	g.C1089T	p.F363F			29362	N	N	SILENT	792	795	795						7	T=785	785	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
F43F	g.C129T	p.F43F			21691	S	S	SILENT	749	749	795						745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F53F	g.C159T	p.F53F			26681	M	M	SILENT	793	795	795						0	T=793	793	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
F543F	g.C1629T	p.F543F			23191	S	S	SILENT	46	46	795						44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
F66F	g.C198T	p.F66F			28471	N	N	SILENT	46	46	795						42	T=4	4	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
F6F	g.C18T	p.F6F			27911	ORF8	ORF8	SILENT	46	46	795						44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
F871F	g.C2613T	p.F871F			2878	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		697	T=52	52	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	795	795	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=795	795	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
G1119S	g.G3355A	p.G1119S			3620	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		740	A=8	8	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G112C	g.G334T	p.G112C			599	ORF1ab	ORF1a	MISSENSE	46	46	795			leader protein	nsp1, produced by both pp1a and pp1ab		45	T=1	1	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G1772G	g.C5316T	p.G1772G			5581	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G295V	g.G884T	p.G295V			1149	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		45	T=1	1	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G328G	g.A984G	p.G328G			29257	N	N	SILENT	748	749	795						737	G=11	11	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G3846S	g.G11536A	p.G3846S			11801	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		45	A=1	1	A	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G4362V	g.G13085T	p.G4362V			13350	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G5063V	g.G15188T	p.G5063V			15452	ORF1ab	ORF1b	MISSENSE	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G5530C	g.G16588T	p.G5530C			16852	ORF1ab	ORF1b	MISSENSE	748	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		744	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G5962C	g.G17884T	p.G5962C			18148	ORF1ab	ORF1b	MISSENSE	749	749	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G5969G	g.C17907T	p.G5969G			18171	ORF1ab	ORF1b	SILENT	46	46	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		42	T=4	4	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G6837G	g.C20511T	p.G6837G			20775	ORF1ab	ORF1b	SILENT	46	46	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
G697R	g.G2089A	p.G697R			2354	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		744	A=5	5	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
G989V	g.G2966T	p.G989V			3231	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		45	T=1	1	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
H3327H	g.T9981C	p.H3327H			10246	ORF1ab	ORF1a	SILENT	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		724	C=25	25	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
H42Y	g.C124T	p.H42Y			27879	ORF7b	ORF7b	MISSENSE	749	749	795						742	T=7	7	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I13T	g.T38C	p.I13T			29595	ORF10	ORF10	MISSENSE	748	749	795						743	C=5	5	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I14T	g.T41C	p.I14T			27242	ORF6	ORF6	MISSENSE	741	749	795						737	C=4	4	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I1839V	g.A5515G	p.I1839V			5780	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		744	G=4	4	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I337I	g.C1011T	p.I337I			29284	N	N	SILENT	46	46	795						41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
I4205V	g.A12613G	p.I4205V			12878	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		0	G=749	749	G	A						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
I529T	g.T1586C	p.I529T			1851	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		40	C=6	6	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
I5475V	g.A16423G	p.I5475V			16687	ORF1ab	ORF1b	MISSENSE	746	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		742	G=4	4	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I5849I	g.T17547C	p.I5849I			17811	ORF1ab	ORF1b	SILENT	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		555	C=194	194	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I712I	g.T2136A	p.I712I			23698	S	S	SILENT	746	749	795						740	A=6	6	A	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
I71I	g.C213T	p.I71I			478	ORF1ab	ORF1a	SILENT	749	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		720	T=29	29	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
K141_F143del	g.421_429delAAGTCATTT	p.K141_F143del			685	ORF1ab	ORF1a		46	46	795			leader protein	nsp1, produced by both pp1a and pp1ab		33	AG=13	13	AG	AAAGTCATTTG						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
K3839K	g.A11517G	p.K3839K			11782	ORF1ab	ORF1a	SILENT	46	46	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		41	G=5	5	G	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
K4483K	g.G13449A	p.K4483K			13713	ORF1ab	ORF1b	SILENT	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	A=46	46	A	G						False	B.1.427	B.1.427=True	de_escalated	05-Mar-2021		
K4483R	g.A13448G	p.K4483R			13712	ORF1ab	ORF1b	MISSENSE	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		742	G=7	7	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
K4664K	g.A13992G	p.K4664K			14256	ORF1ab	ORF1b	SILENT	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		742	G=7	7	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
K5784R	g.A17351G	p.K5784R			17615	ORF1ab	ORF1b	MISSENSE	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		705	G=44	44	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
K67N	g.G201C	p.K67N			25593	ORF3a	ORF3a	MISSENSE	749	749	795						740	C=9	9	C	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
K714R	g.A2141G	p.K714R			2406	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		745	G=4	4	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L141_V143del	g.422_430delTGGGTGTTT	p.L141_V143del			21980	S	S		707	749	795						691	TTTTA=16	16	TTTTA	TTTTTGGGTGTTTA						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L164L	g.C490T	p.L164L			27012	M	M	SILENT	736	749	795						715	T=21	21	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L2062F	g.C6184T	p.L2062F			6449	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		743	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L24F	g.A72C	p.L24F			21634	S	S	MISSENSE	747	749	795						742	C=5	5	C	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L2609F	g.C7825T	p.L2609F			8090	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L2675L	g.C8025T	p.L2675L			8290	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		743	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L3034L	g.C9100T	p.L3034L			9365	ORF1ab	ORF1a	SILENT	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L3180L	g.C9538T	p.L3180L			9803	ORF1ab	ORF1a	SILENT	749	749	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		741	T=8	8	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L3234L	g.C9702T	p.L3234L			9967	ORF1ab	ORF1a	SILENT	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		33	T=13	13	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L3483F	g.C10447T	p.L3483F			10712	ORF1ab	ORF1a	MISSENSE	46	46	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L3585L	g.C10755T	p.L3585L			11020	ORF1ab	ORF1a	SILENT	749	749	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L35L	g.C103T	p.L35L			26625	M	M	SILENT	747	749	795						741	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	748	749	795	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		739	T=9	9	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L3694F	g.C11080T	p.L3694F			11345	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		43	T=3	3	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L3828L	g.C11482T	p.L3828L			11747	ORF1ab	ORF1a	SILENT	749	749	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L3879F	g.C11635T	p.L3879F			11900	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp7	produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L3930F	g.C11788T	p.L3930F			12053	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp7	produced by both pp1a and pp1ab		705	T=44	44	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L4045L	g.C12135T	p.L4045L			12400	ORF1ab	ORF1a	SILENT	749	749	795			nsp8	produced by both pp1a and pp1ab		739	T=10	10	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L4070L	g.C12208T	p.L4070L			12473	ORF1ab	ORF1a	SILENT	46	46	795			nsp8	produced by both pp1a and pp1ab		41	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L4252L	g.C12754T	p.L4252L			13019	ORF1ab	ORF1a	SILENT	45	46	795			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		25	T=20	20	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L4328L	g.G12984A	p.L4328L			13249	ORF1ab	ORF1a	SILENT	749	749	795			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		737	A=12	12	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L451I	g.C1351A	p.L451I			1616	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		736	A=13	13	A	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'W152C'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~1.7-fold increase in binding affinity vs wild type.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	T cell evasion	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf		L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	antibody epitope effects	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	antibody epitope effects	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'S13I', 'W152C'	14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'W152C'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Observed ~2x decrease on average in 16 health workers' convalescent sera.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'W152C'	Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf	'S13I', 'W152C'	In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'S13I', 'W152C'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	convalescent plasma escape	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.32 fold	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	pharmaceutical effectiveness	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	trafficking	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1		We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4]	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	transmissibility	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'W152C'	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	transmissibility	Peng et al. (2021)	https://doi.org/10.1093/cid/ciab283	'S13I', 'W152C'	"Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR"	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	transmissibility	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'S13I', 'W152C', 'D614G'	Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'W152C', 'D614G'	6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'S13I', 'W152C', 'D614G'	Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'S13I', 'W152C'	Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'S13I', 'W152C', 'D614G'	Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccine neutralization efficacy	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'W152C'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	viral load	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'W152C'	Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	793	795	795						0	G=793	793	G	T	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
L52F	g.C154T	p.L52F			25546	ORF3a	ORF3a	MISSENSE	749	749	795						698	T=51	51	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L53F	g.C157T	p.L53F			25549	ORF3a	ORF3a	MISSENSE	46	46	795						45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L5852L	g.C17554T	p.L5852L			17818	ORF1ab	ORF1b	SILENT	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L5905F	g.C17713T	p.L5905F			17977	ORF1ab	ORF1b	MISSENSE	46	46	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L590L	g.G1770A	p.L590L			2035	ORF1ab	ORF1a	SILENT	749	749	795			nsp2	produced by both pp1a and pp1ab		744	A=5	5	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	793	795	795	mask	highly_homoplasic				781	T=12	12	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	793	795	795	mask	highly_homoplasic				781	T=12	12	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	793	795	795	mask	highly_homoplasic				781	T=12	12	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
L6420L	g.C19260T	p.L6420L			19524	ORF1ab	ORF1b	SILENT	786	795	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		771	T=15	15	T	C						False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
L6509L	g.T19527G	p.L6509L			19791	ORF1ab	ORF1b	SILENT	749	749	795			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		745	G=4	4	G	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L6855L	g.T20563C	p.L6855L			20827	ORF1ab	ORF1b	SILENT	46	46	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		45	C=1	1	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L778L	g.T2332C	p.L778L			2597	ORF1ab	ORF1a	SILENT	749	749	795			nsp2	produced by both pp1a and pp1ab		0	C=749	749	C	T						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
L821L	g.C2461T	p.L821L			24023	S	S	SILENT	746	749	795						636	T=110	110	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L865L	g.C2595T	p.L865L			24157	S	S	SILENT	45	46	795						42	T=3	3	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
L889L	g.T2665C	p.L889L			2930	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		742	C=7	7	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
L96F	g.C286T	p.L96F			27679	ORF7a	ORF7a	MISSENSE	738	749	795						726	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
M1193V	g.A3577G	p.M1193V			3842	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		720	G=28	28	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
M234I	g.G702T	p.M234I			28975	N	N	MISSENSE	747	749	795						613	T=134	134	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
M3393I	g.G10179A	p.M3393I			10444	ORF1ab	ORF1a	MISSENSE	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		743	A=6	6	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
M5900I	g.G17700T	p.M5900I			17964	ORF1ab	ORF1b	MISSENSE	46	46	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		44	T=2	2	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
M5987V	g.A17959G	p.M5987V			18223	ORF1ab	ORF1b	MISSENSE	749	749	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		743	G=6	6	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
M85T	g.T254C	p.M85T			519	ORF1ab	ORF1a	MISSENSE	747	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		740	C=7	7	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N1026S	g.A3077G	p.N1026S			3342	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		45	G=1	1	G	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
N162N	g.C486T	p.N162N			751	ORF1ab	ORF1a	SILENT	749	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		743	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N234N	g.C702T	p.N234N			22264	S	S	SILENT	749	749	795						733	T=16	16	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N2405S	g.A7214G	p.N2405S			7479	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		739	G=10	10	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N280N	g.T840C	p.N280N			22402	S	S	SILENT	46	46	795						44	C=2	2	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
N2894N	g.C8682T	p.N2894N			8947	ORF1ab	ORF1a	SILENT	749	749	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		4	T=745	745	T	C						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
N3007N	g.C9021T	p.N3007N			9286	ORF1ab	ORF1a	SILENT	748	749	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		611	T=137	137	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N4235N	g.C12705T	p.N4235N			12970	ORF1ab	ORF1a	SILENT	749	749	795			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		697	T=52	52	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N4795N	g.C14385T	p.N4795N			14649	ORF1ab	ORF1b	SILENT	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		43	T=3	3	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
N5083N	g.T15249C	p.N5083N			15513	ORF1ab	ORF1b	SILENT	46	46	795	caution	single_src,ambiguous	RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41	C=5	5	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
N6335N	g.C19005T	p.N6335N			19269	ORF1ab	ORF1b	SILENT	749	749	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		677	T=72	72	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N810N	g.C2430T	p.N810N			2695	ORF1ab	ORF1a	SILENT	749	749	795			nsp2	produced by both pp1a and pp1ab		735	T=14	14	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
N99N	g.C297T	p.N99N			21859	S	S	SILENT	712	749	795						704	T=8	8	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P104S	g.C310T	p.P104S			25702	ORF3a	ORF3a	MISSENSE	46	46	795						42	T=4	4	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P1213L	g.C3638T	p.P1213L			3903	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		721	T=27	27	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P1640L	g.C4919T	p.P1640L			5184	ORF1ab	ORF1a	MISSENSE	45	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P2018T	g.C6052A	p.P2018T			6317	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		45	A=1	1	A	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P2079S	g.C6235T	p.P2079S			6500	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P25P	g.T75C	p.P25P			25467	ORF3a	ORF3a	SILENT	46	46	795						40	C=6	6	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P26S	g.C76T	p.P26S			21638	S	S	MISSENSE	747	749	795						743	T=4	4	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P26S	g.C76T	p.P26S			21638	S	S	MISSENSE	747	749	795						743	T=4	4	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P26S	g.C76T	p.P26S			21638	S	S	MISSENSE	747	749	795						743	T=4	4	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P302P	g.G906T	p.P302P			29179	N	N	SILENT	46	46	795						45	T=1	1	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P309T	g.C925A	p.P309T			1190	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		43	A=3	3	A	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P3395P	g.C10185T	p.P3395P			10450	ORF1ab	ORF1a	SILENT	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		719	T=30	30	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P34L	g.C101T	p.P34L			27494	ORF7a	ORF7a	MISSENSE	787	795	795						759	T=28	28	T	C						False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
P3504P	g.T10512C	p.P3504P			10777	ORF1ab	ORF1a	SILENT	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		716	C=33	33	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P36P	g.G108T	p.P36P			28001	ORF8	ORF8	SILENT	748	749	795						722	T=26	26	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P371S	g.C1111T	p.P371S			1376	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		734	T=15	15	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
P4715L	g.C14144T	p.P4715L			14408	ORF1ab	ORF1b	MISSENSE	795	795	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=795	795	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
P5377L	g.C16130T	p.P5377L			16394	ORF1ab	ORF1b	MISSENSE	46	46	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	T=46	46	T	C						False	B.1.427	B.1.427=True	de_escalated	05-Mar-2021		
P769H	g.C2306A	p.P769H			2571	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		43	A=3	3	A	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
P80S	g.C238T	p.P80S			503	ORF1ab	ORF1a	MISSENSE	46	46	795			leader protein	nsp1, produced by both pp1a and pp1ab		33	T=13	13	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
Q57H	g.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	795	795	795						0	T=795	795	T	G						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
Q607H	g.G1821T	p.Q607H			23383	S	S	MISSENSE	749	749	795						737	T=12	12	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Q779E	g.C2335G	p.Q779E			23897	S	S	MISSENSE	746	749	795						730	G=16	16	G	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Q836L	g.A2507T	p.Q836L			24069	S	S	MISSENSE	746	749	795						738	T=8	8	T	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
R1464W	g.C4390T	p.R1464W			4655	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		735	T=13	13	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
R398C	g.C1192T	p.R398C			1457	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		246	T=503	503	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
R3993C	g.C11977T	p.R3993C			12242	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp8	produced by both pp1a and pp1ab		743	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
R7014C	g.C21040T	p.R7014C			21304	ORF1ab	ORF1b	MISSENSE	745	749	795	caution	neighbour_linked	2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		730	T=15	15	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
R7014R	g.C21042T	p.R7014R			21306	ORF1ab	ORF1b	SILENT	746	749	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		739	T=7	7	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S1252F	g.C3755T	p.S1252F			25317	S	S	MISSENSE	46	46	795						40	T=6	6	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'W152C', 'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		The S13I mutation dampened binding of 5 mAbs and abrogated binding of 5 additional mAbs out of 11 neutralizing mAbs evaluated. Predicted to shift the signal peptide cleavage site from S13-Q14 to C15-V16, which can affect NTD conformation.  PG: in saying S12F does not shift the signal peptide nor affect mAb binding, this manuscript appears to contradict the  text of McCallum et al.'s earlier 2021 manuscript stating that S12F *does* affected some mAb binding via putative signal peptide shift.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'W152C'	The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'W152C', 'L452R'	14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'W152C', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	convalescent plasma escape	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'W152C', 'L452R'	Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf	'W152C', 'L452R'	In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'W152C', 'L452R'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	transmissibility	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'W152C', 'L452R'	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	transmissibility	Peng et al. (2021)	https://doi.org/10.1093/cid/ciab283	'W152C', 'L452R'	"Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR"	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'W152C', 'L452R', 'D614G'	Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccine neutralization efficacy	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'W152C', 'L452R', 'D614G'	6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'W152C', 'L452R', 'D614G'	Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccine neutralization efficacy	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'W152C', 'L452R'	Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'W152C', 'L452R', 'D614G'	Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'W152C', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S13I	g.G38T	p.S13I			21600	S	S	MISSENSE	794	795	795						0	T=794	794	T	G	viral load	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'W152C', 'L452R'	Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
S1468F	g.C4403T	p.S1468F			4668	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		744	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S1506L	g.C4517T	p.S1506L			4782	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		719	T=29	29	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S201N	g.G602A	p.S201N			28875	N	N	MISSENSE	749	749	795						745	A=4	4	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S202G	g.A604G	p.S202G			28877	N	N	MISSENSE	749	749	795						744	G=5	5	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S2103F	g.C6308T	p.S2103F			6573	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		744	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S2151I	g.G6452T	p.S2151I			6717	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		45	T=1	1	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
S2535L	g.C7604T	p.S2535L			7869	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
S256S	g.A768G	p.S256S			22330	S	S	SILENT	740	749	795						734	G=6	6	G	A						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S2599S	g.A7797G	p.S2599S			8062	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	G=2	2	G	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
S308L	g.C923T	p.S308L			1188	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S3158T	g.G9473C	p.S3158T			9738	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	C=46	46	C	G						False	B.1.427	B.1.427=True	de_escalated	05-Mar-2021		
S318L	g.C953T	p.S318L			1218	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
S33I	g.G98T	p.S33I			28371	N	N	MISSENSE	749	749	795						745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S37F	g.C110T	p.S37F			27503	ORF7a	ORF7a	MISSENSE	741	749	795						733	T=8	8	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S443F	g.C1328T	p.S443F			1593	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp2	produced by both pp1a and pp1ab		744	T=5	5	T	C	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody	False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S549S	g.C1647T	p.S549S			1912	ORF1ab	ORF1a	SILENT	749	749	795			nsp2	produced by both pp1a and pp1ab		741	T=8	8	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
S929S	g.T2787C	p.S929S			24349	S	S	SILENT	745	749	795						0	C=745	745	C	T						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
S94S	g.C282T	p.S94S			21844	S	S	SILENT	710	749	795						706	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T1022I	g.C3065T	p.T1022I			3330	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		743	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T1344K	g.C4031A	p.T1344K			4296	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		743	A=6	6	A	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T1426T	g.C4278T	p.T1426T			4543	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T151I	g.C452T	p.T151I			25844	ORF3a	ORF3a	MISSENSE	46	46	795						33	T=13	13	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T1864T	g.G5592A	p.T1864T			5857	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		697	A=52	52	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T205I	g.C614T	p.T205I			28887	N	N	MISSENSE	795	795	795						0	T=795	795	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
T20T	g.C60T	p.T20T			21622	S	S	SILENT	45	46	795						40	T=5	5	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T217I	g.C650T	p.T217I			26042	ORF3a	ORF3a	MISSENSE	747	749	795						743	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T21I	g.C62T	p.T21I			27263	ORF6	ORF6	MISSENSE	786	795	795						763	T=23	23	T	C						False	B.1.427, B.1.429	B.1.429=False, B.1.427=False	de_escalated	05-Mar-2021		
T265I	g.C794T	p.T265I			1059	ORF1ab	ORF1a	MISSENSE	795	795	795			nsp2	produced by both pp1a and pp1ab		0	T=795	795	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
T2676T	g.C8028T	p.T2676T			8293	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T269M	g.C806T	p.T269M			26198	ORF3a	ORF3a	MISSENSE	747	749	795						742	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T2877I	g.C8630T	p.T2877I			8895	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		42	T=4	4	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T32I	g.C95T	p.T32I			25487	ORF3a	ORF3a	MISSENSE	749	749	795						737	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T3459M	g.C10376T	p.T3459M			10641	ORF1ab	ORF1a	MISSENSE	749	749	795			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		736	T=13	13	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T345T	g.C1035T	p.T345T			22597	S	S	SILENT	46	46	795						25	T=21	21	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T34A	g.A100G	p.T34A			25492	ORF3a	ORF3a	MISSENSE	46	46	795						45	G=1	1	G	A						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T3940I	g.C11819T	p.T3940I			12084	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp7	produced by both pp1a and pp1ab		738	T=10	10	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T417I	g.C1250T	p.T417I			29523	N	N	MISSENSE	748	749	795						742	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T4304I	g.C12911T	p.T4304I			13176	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T5131I	g.C15392T	p.T5131I			15656	ORF1ab	ORF1b	MISSENSE	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T531T	g.T1593C	p.T531T			23155	S	S	SILENT	748	749	795						626	C=122	122	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T5420I	g.C16259T	p.T5420I			16523	ORF1ab	ORF1b	MISSENSE	749	749	795			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T5956I	g.C17867T	p.T5956I			18131	ORF1ab	ORF1b	MISSENSE	46	46	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T6833I	g.C20498T	p.T6833I			20762	ORF1ab	ORF1b	MISSENSE	46	46	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
T6949I	g.C20846T	p.T6949I			21110	ORF1ab	ORF1b	MISSENSE	746	749	795			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		734	T=12	12	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
T781I	g.C2342T	p.T781I			2607	ORF1ab	ORF1a	MISSENSE	46	46	795			nsp2	produced by both pp1a and pp1ab		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V100L	g.G298T	p.V100L			28191	ORF8	ORF8	MISSENSE	748	749	795						612	T=136	136	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V1065V	g.G3195T	p.V1065V			24757	S	S	SILENT	749	749	795						745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V1118V	g.C3354A	p.V1118V			3619	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40	A=6	6	A	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V1299L	g.G3895T	p.V1299L			4160	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		744	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V1299V	g.G3897T	p.V1299V			4162	ORF1ab	ORF1a	SILENT	46	46	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		44	T=2	2	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V225A	g.T674C	p.V225A			26066	ORF3a	ORF3a	MISSENSE	46	46	795						40	C=6	6	C	T						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V2421V	g.C7263T	p.V2421V			7528	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V3690V	g.G11070T	p.V3690V			11335	ORF1ab	ORF1a	SILENT	747	749	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		742	T=5	5	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V3718F	g.G11152T	p.V3718F			11417	ORF1ab	ORF1a	MISSENSE	749	749	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V4691I	g.G14071A	p.V4691I			14335	ORF1ab	ORF1b	MISSENSE	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		745	A=4	4	A	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V5092V	g.C15276T	p.V5092V			15540	ORF1ab	ORF1b	SILENT	749	749	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		702	T=47	47	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V5156V	g.G15468T	p.V5156V			15732	ORF1ab	ORF1b	SILENT	46	46	795			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41	T=5	5	T	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V6212F	g.G18634T	p.V6212F			18895	ORF1ab	ORF1b	MISSENSE	748	749	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		709	TTTA=30	30	TTTA	TTTGTTA						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V6212del	g.18634_18636delGTT	p.V6212del			18895	ORF1ab	ORF1b		748	749	795			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		709	TTTTTTA=9	9	TTTTTTA	TTTGTTA						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V627F	g.G1879T	p.V627F			2144	ORF1ab	ORF1a	MISSENSE	748	749	795			nsp2	produced by both pp1a and pp1ab		723	T=25	25	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
V710V	g.C2130T	p.V710V			2395	ORF1ab	ORF1a	SILENT	749	749	795			nsp2	produced by both pp1a and pp1ab		0	T=749	749	T	C						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
V72I	g.G214A	p.V72I			28487	N	N	MISSENSE	46	46	795						45	A=1	1	A	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V81I	g.G241A	p.V81I			28134	ORF8	ORF8	MISSENSE	46	46	795						45	A=1	1	A	G						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
V90F	g.G268T	p.V90F			25660	ORF3a	ORF3a	MISSENSE	749	749	795						745	T=4	4	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		The W152C mutation reduced recognition of six NTD neutralizing mAbs, including a complete loss of binding for two of them, with a complementary pattern to that observed for S13I (also found in lineage B.1.427/B.1.429) out of 11 neutralizing mAbs evaluated.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'S13I'	The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'S13I', 'L452R'	14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	convalescent plasma escape	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'L452R'	Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf	'S13I', 'L452R'	In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs. 	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'S13I', 'L452R'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	trafficking	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1		Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to  D614G alone in 293T cells and human airway organoids.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	transmissibility	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'L452R'	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	transmissibility	Peng et al. (2021)	https://doi.org/10.1093/cid/ciab283	'S13I', 'L452R'	"Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR"	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'S13I', 'L452R', 'D614G'	Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccine neutralization efficacy	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'L452R', 'D614G'	6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'S13I', 'L452R', 'D614G'	Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccine neutralization efficacy	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'S13I', 'L452R'	Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'S13I', 'L452R', 'D614G'	Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'S13I', 'L452R'	This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W152C	g.G456T	p.W152C			22018	S	S	MISSENSE	792	795	795						0	T=792	792	T	G	viral load	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	'S13I', 'L452R'	Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.	False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
W45R	g.T133C	p.W45R			28026	ORF8	ORF8	MISSENSE	748	749	795						733	C=15	15	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y107H	g.T319C	p.Y107H			25711	ORF3a	ORF3a	MISSENSE	749	749	795						745	C=4	4	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y1110Y	g.T3330C	p.Y1110Y			24892	S	S	SILENT	749	749	795						741	C=8	8	C	T						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y113Y	g.C339T	p.Y113Y			25731	ORF3a	ORF3a	SILENT	748	749	795						581	T=167	167	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y118Y	g.C354T	p.Y118Y			619	ORF1ab	ORF1a	SILENT	749	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		719	T=30	30	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y136Y	g.C408T	p.Y136Y			673	ORF1ab	ORF1a	SILENT	748	749	795			leader protein	nsp1, produced by both pp1a and pp1ab		743	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y1700Y	g.C5100T	p.Y1700Y			5365	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y2489Y	g.C7467T	p.Y2489Y			7732	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		744	T=5	5	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y2560Y	g.C7680T	p.Y2560Y			7945	ORF1ab	ORF1a	SILENT	749	749	795			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		745	T=4	4	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
Y3098Y	g.C9294T	p.Y3098Y			9559	ORF1ab	ORF1a	SILENT	46	46	795			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
Y3803Y	g.C11409T	p.Y3803Y			11674	ORF1ab	ORF1a	SILENT	46	46	795			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
g.A-2T	g.A-2T				28272	N	intergenic		795	795	795						0	T=795	795	T	A						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
g.C-13T	g.C-13T				29545	ORF10	intergenic		748	749	795						730	T=18	18	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
g.C-1T	g.C-1T				27393	ORF7a	intergenic		742	749	795						736	T=6	6	T	C						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
g.C-25T	g.C-25T				241	ORF1ab	intergenic		795	795	795						0	T=795	795	T	C						False	B.1.427, B.1.429	B.1.427=True, B.1.429=True	de_escalated	05-Mar-2021		
g.C-3T	g.C-3T				29555	ORF10	intergenic		46	46	795						45	T=1	1	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
g.C-44T	g.C-44T				222	ORF1ab	intergenic		46	46	795						33	T=13	13	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
g.C-80T	g.C-80T				186	ORF1ab	intergenic		46	46	795						44	T=2	2	T	C						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
g.G-4T	g.G-4T				27890	ORF8	intergenic		749	749	795						0	T=749	749	T	G						False	B.1.429	B.1.429=True	de_escalated	05-Mar-2021		
g.G29706C	g.G29706C				29706	intergenic	intergenic		747	749	795						717	C=30	30	C	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
g.G29773T	g.G29773T				29773	intergenic	intergenic		68	749	795						57	T=11	11	T	G						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
g.GAGTGTACA29755GA	g.GAGTGTACA29755GA				29755	intergenic	intergenic		45	46	795						40	GA=5	5	GA	GAGTGTACA						False	B.1.427	B.1.427=False	de_escalated	05-Mar-2021		
g.TACGATCGAGTGTACA29748TA	g.TACGATCGAGTGTACA29748TA				29748	intergenic	intergenic		724	749	795						720	TA=4	4	TA	TACGATCGAGTGTACA						False	B.1.429	B.1.429=False	de_escalated	05-Mar-2021		
